This pilot study examines how we measure some of the side effects that can occur during and after taxane-based breast cancer chemotherapy. Taxane is a widely used chemotherapy agent due to its effectiveness, but it can also cause serious side effects. One of these side effects is Chemotherapy Induced Peripheral Neuropathy (CIPN). CIPN may present as numbness and/or tingling in the toes, feet, fingers or hands. Some people may also report a decrease in sensitivity, hypersensitivity to certain stimuli, pain, sensory changes and even balance problems. Despite the importance of these symptoms, there are currently no clear guidelines for effectively assessing, preventing or even slowing the development of CIPN. 

​

The purpose of this project is to examine how well assessment tools measure CIPN and whether they are equally good for younger and older people. Data were collected from women with breast cancer at four time points in their care trajectory. At the assessment meetings, the research team collected sociodemographic information and conducted physical tests and collected responses to self-report measures of symptoms and wellbeing.    

​

Through the dedicated participation of these women, we will be able to obtain a better understanding of the quality of the current tools used for CIPN.